Gahanna, OH – According to filings with the U.S. Securities and Exchange Commission, IR Medtek is raising $2,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Douglas Cohen played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About IR Medtek
IR Medtek LLC was founded in early 2019 by Doug Cohen, three other co-founders, and in collaboration with the Ohio State Innovation Fund. The company is the licensor of ground-breaking technology developed at The Ohio State University and the James Cancer Hospital for the early non-invasive diagnosis of skin and other cancers. The company is currently conducting further research on this technology ahead of a planned clinical study in 2020. Upon validation of the technology in a clinical context, the company will proceed with commercialization of its technology, for which it expects there to be multiple applications. The companys mission is to improve healthcare outcomes through timely, accurate and non-invasive detection of cancers.

To learn more about IR Medtek, visit http://www.irmedtek.com/

Contact:
Douglas Cohen, Chief Executive Officer
614-226-6046
https://www.linkedin.com/in/doug-cohen-64761410/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved